4KScore Test

  • Medical Author:
    Kevin C. Zorn, MD, FRCSC, FACS

    Dr. Kevin Zorn is a dual-board-certified (US and Canada), minimally-invasive uro-oncology, fellowship trained urologist at the University of Chicago. His main focus of clinical and scientific interest is in the surgical treatment of renal and prostate cancer. He is also an expert in performing surgery with the DaVinci Surgical Robotic System to manage localized prostate cancer and small renal masses. Dr. Zorn studied medicine and urology at McGill University in Montréal.

  • Medical Editor: Melissa Conrad Stöppler, MD
    Melissa Conrad Stöppler, MD

    Melissa Conrad Stöppler, MD

    Melissa Conrad Stöppler, MD, is a U.S. board-certified Anatomic Pathologist with subspecialty training in the fields of Experimental and Molecular Pathology. Dr. Stöppler's educational background includes a BA with Highest Distinction from the University of Virginia and an MD from the University of North Carolina. She completed residency training in Anatomic Pathology at Georgetown University followed by subspecialty fellowship training in molecular diagnostics and experimental pathology.

View the Prostate Cancer Slideshow Pictures

What is the 4K biomarker?

The 4K biomarker is a blood test that measures four different proteins in the blood to assess prostate cancer risk. The blood test that assesses these biomarkers is called the 4KScore Test. It suggests the possible risk that a significant prostate cancer would be found.

What does the 4KScore Test measure?

The 4Kscore Test relies on the measurement of four prostate-specific kallikreins in the blood: Total PSA, Free PSA, Intact PSA, and Human Kallikrein 2 (hK2).

What is the role of the 4KScore Test in prostate cancer screening?

The 4Kscore Test helps clarify the biopsy decision-making process by determining a patient-specific probability for finding aggressive, Gleason score 7 or higher prostate cancer upon biopsy. These are the aggressive prostate cancers that always require medical treatment or intervention. The blood test results are combined in an algorithm with patient age, digital rectal exam findings (nodules vs. no nodules), and prior negative biopsy (yes or no) to give physicians a personalized score for individual patients. The 4Kscore Test predicts the risk percent score from less than 1% to greater than 95% of a man having aggressive cancer in a prospective biopsy.

How does the 4KScore Test minimize unnecessary prostate biopsies?

The 4Kscore Test has undergone extensive clinical research and laboratory test validation. Based on the results of clinical studies, as many as 30% to 58% of biopsies are avoidable using the 4Kscore Test.

REFERENCE:

Punnen, S., et al. "Finding the Wolf in Sheep’s Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer." Reviews in Urology 17.1 (2015): 3-13.

Quick GuideProstate Cancer Symptoms, PSA Test, Treatments

Prostate Cancer Symptoms, PSA Test, Treatments

Subscribe to MedicineNet's Cancer Report Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Reviewed on 1/15/2016
References
REFERENCE:

Punnen, S., et al. "Finding the Wolf in Sheep’s Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer." Reviews in Urology 17.1 (2015): 3-13.

Health Solutions From Our Sponsors